Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer

早期乳腺癌新兴基因组测试的经济评估

• 批准号: 7256700
• 负责人: Ya-Chen Tina Shih
• 金额: $ 7.7万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-15 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7256700
• 关键词: Clinical; Early treatment; Economics; Evaluation; Genome; Genomics; Health; Healthcare; Human; Human Genome Project; Licensing; Medical Technology; Methods; Numbers; Patients; Performance; Pharmacogenomics; Physicians; Purpose; Range; Safety; Societies; Staging; Technology; Testing; Woman; base; cost; cost effectiveness; improved; innovation; malignant breast neoplasm; performance tests; prognostic

DESCRIPTION (provided by applicant): Emerging medical technologies are substantially improving our health care options, but often at considerable added cost. Cost-effectiveness and affordability are described as the fourth and fifth hurdles for new medical technologies, following the traditional three hurdles for licensing requirements: safety, efficacy, and quality. The Human Genome Project offers ample opportunity to improve human health through innovative genome-based technologies that have only recently become available. A number of genomic prognostic and predictive tests have been developed to assist physicians in providing better treatment for patients with early-stage breast cancer (ESBC). Clinical use of these emerging genomic tests will depend not only on the accuracy of the tests but also on their economic impacts to the society. The purpose of this study is to use methods of economic evaluation to examine the relationship between the performance of pharmacogenomic prognostic and predictive tests and their costs over a plausible range of test performance and costs for women with ESBC in the context of costeffectiveness and affordability. The specific aims are the following: 1. To compare the cost-effectiveness of using pharmacogenomic prognostic tests versus current practices in the treatment of ESBC 2. To assess the cost-effectiveness of using pharmacogenomic predictive tests versus current practices in the treatment of ESBC 3. To evaluate the cost-effectiveness of using a combination of pharmacogenomic prognostic and predictive tests versus current practices in the treatment of ESBC 4. To estimate the budgetary impact of the emerging pharmacogenomic prognostic and/or predictive tests

描述（由申请人提供）：新兴医疗技术正在极大地改善我们的医疗保健选择，但往往会增加相当大的成本。成本效益和负担能力被描述为继传统的许可要求的三个障碍：安全性、有效性和质量之后，新医疗技术的第四和第五个障碍。人类基因组计划提供了充足的机会，通过最近才出现的基于基因组的创新技术来改善人类健康。已经开发出许多基因组预后和预测测试来帮助医生为早期乳腺癌 (ESBC) 患者提供更好的治疗。这些新兴基因组测试的临床应用不仅取决于测试的准确性，还取决于它们对社会的经济影响。本研究的目的是使用经济评估方法，在成本效益和可负担性的背景下，在 ESBC 女性的测试性能和成本的合理范围内，检查药物基因组预后和预测测试的性能与其成本之间的关系。具体目标如下： 1. 比较使用药物基因组学预后测试与当前治疗 ESBC 的方法的成本效益 2. 评估使用药物基因组预测测试与当前 ESBC 治疗实践的成本效益 3. 评估结合使用药物基因组预后和预测测试与当前 ESBC 治疗实践的成本效益 4. 估计新兴药物基因组预后和/或预测测试的预算影响